Recursion Year-End 2024 Recap

(1:36)

Live from NeurIPS: MolPhenix - Best Paper Winner from the Foundation Models for Science Workshop

(2:5)

Live from NeurIPS: Faster, More Accurate Generation of Molecular Properties with ET-Flow

(3:32)

Follow Us to the MolPhenix Spotlight Paper at NeurIPS!

(20)

CDK7 Interim Data Update Call

(33:40)

Presenting Interim Phase 1 Clinical Data for REC-617 -- a Potential Best-in-Class CDK7 Inhibitor

(21)

First Patient Dosed in Recursion's Phase 1/2 Clinical Study of REC-1245

(17)

Recursion on the Nasdaq Tower

(14)

A New TechBio Powerhouse

(30)

November 20 Update Call

(33:33)

Recursion Pharmaceuticals Stock Analysis and Explanation : Ticker Symbol RXRX

(3:30)

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

(7:24)

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

(4:49)

[Nov26@6:50PM] $RXRX (Recursion)

(26)

The Largest Supercomputer in Pharma

(2:12)

[May22@6:50PM] $RXRX (Recursion)

(22)

Recursion CEO Chris Gibson talks integrating AI into drug development process

(4:52)

Download Day 2024 — Fireside Chat: NVIDIA Founder \u0026 CEO Jensen Huang and Recursion's Chris Gibson

(35:3)

What's Next? - RXRX Stock Price Prediction - RXRX Stock Analysis | Recursion Pharmaceuticals Stock

(2:8)

[Apr23@6:50PM] $RXRX (Recursion)

(29)

November 20 Update Call

(33:33)

Download Day 2024 Full Day

(4:16)

Revealed: Eric Fry's \

(6:12)

The Untold Story: Cathie Wood's Bold Move in Recursion Pharmaceutical

(5:12)

Recursion CEO Chris Gibson: There's real opportunity to leverage A.I. to speed up drug development

(3:24)

What's Next? - RXRX Stock Price Prediction - RXRX Stock Analysis | Recursion Pharmaceuticals Stock

(1:51)

[Jun27@6:50PM] -$RXRX (Recursion)

(22)

READY TO MOVE HIGHER | $RXRX STOCK ANALYSIS | RECURSION PHARMACEUTICALS INC STOCK

(2:12)